Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Bad financial results growth rate -47.2% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-11.0%)
  • Dividend yield for the last twelve months 3.1%
  • Free cash flow yield -4.8% (LTM)
  • Share price is 54.7% higher than minimum and -0.4% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (43.0x vs 25.4x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.3 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+0.4%)204.94
year average price 179.68  


year start price 178.99 2024-02-27

min close price 154.79 2024-05-29

max close price 204.08 2025-02-24

current price 204.08 2025-02-25
Common stocks: 1 768 480 508

Dividend Yield:  3.1%
FCF Yield LTM: -4.8%
EV / LTM EBITDA: 43.0x
EV / Sales: 7.5x
Margin (EBITDA LTM / Revenue): 17.5%

Target EV / EBITDA (hist percentile): 25.4x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 360 912
Net Debt ($m): 63 833
EV (Enterprise Value): 424 745
EBITDA LTM (млн $): 9 882
EV / LTM EBITDA: 43.0x
Price to Book: 59.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-02-23seekingalpha.com

Why AbbVie Remains A Strong Buy For Long-Term Investors

2025-02-21zacks.com

4 Seniors & Aging Demographics Stocks to Watch Right Now

2025-02-20fool.com

2 Magnificent Dividend Growth Stocks to Load Up On Right Now

2025-02-19seekingalpha.com

AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant

2025-02-18seekingalpha.com

AbbVie Appears Ready To Move Higher

2025-02-15fool.com

Is AbbVie Stock a Buy Now?

2025-02-14seekingalpha.com

AbbVie: An Undervalued Dividend Aristocrat

2025-02-14247wallst.com

AbbVie Just Paid Investors: Here's How Much They Received

2025-02-14prnewswire.com

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

2025-02-12globenewswire.com

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ABBV ABBV ABBV ABBV ABBV ABBV ABBV ABBV ABBV
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-07 2024-05-03 2024-02-20 2023-11-06 2023-08-07 2023-05-05 2023-02-17 2022-11-04
acceptedDate 2024-11-04 14:19:33 2024-08-07 15:00:51 2024-05-03 11:04:11 2024-02-20 12:45:17 2023-11-06 13:01:04 2023-08-07 13:10:46 2023-05-05 12:54:58 2023-02-17 12:54:29 2022-11-04 13:07:23
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 14 460M 14 462M 12 310M 14 301M 13 927M 13 865M 12 225M 15 121M 14 812M
costOfRevenue 4 212M 2 176M 4 082M 2 386M 6 485M 4 240M 3 986M 4 170M 5 022M
grossProfit 10 248M 12 286M 8 228M 11 915M 7 442M 9 625M 8 239M 10 951M 9 790M
grossProfitRatio 0.709 0.85 0.668 0.833 0.534 0.694 0.674 0.724 0.661
researchAndDevelopmentExpenses 2 130M 1 917M 1 939M 1 921M 1 723M 1 733M 2 292M 1 790M 1 614M
generalAndAdministrativeExpenses 0 0 0 1 406M 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 2 200M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4 205M 3 342M 3 300M 3 606M 3 372M 3 268M 3 039M 3 417M 3 304M
otherExpenses 82M -1 947M -586M -1 889M 95M -1 412M -10M -1 000 000 229M
operatingExpenses 6 417M 7 206M 5 239M 7 416M 5 095M 4 832M 5 321M 5 206M 5 147M
costAndExpenses 10 629M 10 464M 9 321M 9 802M 11 580M 9 072M 9 307M 9 376M 10 169M
interestIncome 0 220M 207M 186M 157M 98M 99M 90M 63M
interestExpense 591M 726M 660M 363M 398M 552M 553M 566M 560M
depreciationAndAmortization 2 079M 2 131M 2 074M 2 076M 161M 2 260M 2 127M 2 157M 2 559M
ebitda 4 933M 7 129M 5 063M 4 183M 2 442M 6 773M 4 895M 6 028M 7 162M
ebitdaratio 0.341 0.351 0.411 0.292 0.175 0.488 0.4 0.399 0.484
operatingIncome 3 831M 3 998M 2 989M 4 499M 2 281M 4 513M 2 768M 3 871M 4 603M
operatingIncomeRatio 0.265 0.276 0.243 0.315 0.164 0.325 0.226 0.256 0.311
totalOtherIncomeExpensesNet -1 747M -1 852M -1 234M -3 287M 4M -1 729M -1 989M -906M -203M
incomeBeforeTax 2 084M 2 146M 1 755M 1 212M 1 953M 2 610M 475M 2 965M 4 400M
incomeBeforeTaxRatio 0.144 0.148 0.143 0.085 0.14 0.188 0.039 0.196 0.297
incomeTaxExpense 520M 773M 383M 388M 172M 583M 234M 493M 448M
netIncome 1 561M 1 370M 1 369M 822M 1 778M 2 024M 239M 2 473M 3 949M
netIncomeRatio 0.108 0.095 0.111 0.057 0.128 0.146 0.02 0.164 0.267
eps 0.88 0.78 0.77 0.46 1 1.14 0.13 1.4 2.22
epsdiluted 0.88 0.78 0.77 0.46 1 1.14 0.13 1.38 2.21
weightedAverageShsOut 1 769M 1 769M 1 769M 1 766M 1 767M 1 767M 1 770M 1 769M 1 771M
weightedAverageShsOutDil 1 772M 1 771M 1 773M 1 772M 1 771M 1 771M 1 776M 1 778M 1 776M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ABBV ABBV ABBV ABBV ABBV ABBV ABBV ABBV ABBV
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-07 2024-05-03 2024-02-20 2023-11-06 2023-08-07 2023-05-05 2023-02-17 2022-11-04
acceptedDate 2024-11-04 14:19:33 2024-08-07 15:00:51 2024-05-03 11:04:11 2024-02-20 12:45:17 2023-11-06 13:01:04 2023-08-07 13:10:46 2023-05-05 12:54:58 2023-02-17 12:54:29 2022-11-04 13:07:23
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 7 257M 13 130M 18 067M 12 814M 13 287M 8 759M 6 711M 9 201M 11 832M
shortTermInvestments 28M 27M 2M 2M 3M 7M 11M 28M 47M
cashAndShortTermInvestments 7 285M 13 157M 18 069M 12 816M 13 290M 8 766M 6 722M 9 229M 11 879M
netReceivables 11 472M 11 724M 11 949M 11 155M 11 412M 11 491M 11 473M 11 254M 10 743M
inventory 4 450M 4 218M 4 245M 4 099M 3 981M 4 055M 3 833M 3 579M 3 172M
otherCurrentAssets 4 578M 4 717M 4 608M 4 932M 4 541M 4 540M 4 460M 4 401M 4 570M
totalCurrentAssets 27 785M 33 816M 38 871M 33 002M 33 224M 28 852M 26 488M 28 463M 30 364M
propertyPlantEquipmentNet 5 141M 5 023M 4 980M 4 989M 4 934M 4 943M 4 931M 4 935M 4 893M
goodwill 35 295M 33 386M 33 426M 32 293M 32 091M 32 224M 32 220M 32 156M 31 726M
intangibleAssets 66 646M 60 243M 62 225M 55 610M 58 603M 62 862M 64 848M 67 439M 68 725M
goodwillAndIntangibleAssets 101 941M 93 629M 95 651M 87 903M 90 694M 95 086M 97 068M 99 595M 100 451M
longTermInvestments 267M 272M 311M 304M 275M 288M 257M 241M 235M
taxAssets 0 0 2 722M 1 952M 2 044M 2 124M 2 110M 2 190M 0
otherNonCurrentAssets 8 288M 9 197M 6 339M 6 561M 5 050M 4 074M 3 690M 3 381M 5 382M
totalNonCurrentAssets 115 637M 108 121M 110 003M 101 709M 102 997M 106 515M 108 056M 110 342M 110 961M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 143 422M 141 937M 148 874M 134 711M 136 221M 135 367M 134 544M 138 805M 141 325M
accountPayables 0 0 31 258M 3 688M 29 570M 0 0 2 934M 0
shortTermDebt 12 570M 12 586M 10 196M 7 191M 5 115M 5 203M 2 801M 4 136M 9 207M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 -29 570M 0 0 0 1 972M
otherCurrentLiabilities 30 492M 29 329M 68M 26 962M 29 658M 27 036M 24 789M 22 468M 21 533M
totalCurrentLiabilities 43 062M 41 915M 41 522M 37 841M 34 773M 32 239M 27 590M 29 538M 32 712M
longTermDebt 58 509M 58 048M 63 805M 52 194M 55 631M 55 812M 59 292M 59 135M 60 399M
deferredRevenueNonCurrent 0 0 0 3 720M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 2 749M 2 726M 2 722M 1 952M 2 044M 2 124M 2 110M 2 190M 1 972M
otherNonCurrentLiabilities 33 031M 32 427M 32 778M 28 607M 31 644M 32 294M 32 249M 30 655M 81 407M
totalNonCurrentLiabilities 94 289M 93 201M 99 305M 86 473M 89 319M 90 230M 93 651M 91 980M 92 586M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 762M 0 0 0 0 0
totalLiabilities 137 351M 135 116M 140 827M 124 314M 124 092M 122 469M 121 241M 121 518M 125 298M
preferredStock 0 0 2 366M 0 0 0 0 0 0
commonStock 18M 18M 18M 18M 18M 18M 18M 18M 18M
retainedEarnings -4 964M -3 768M -2 384M -1 000M 933M 1 789M 2 393M 4 784M 4 953M
accumulatedOtherComprehensiveIncomeLoss -2 334M -2 513M -2 454M -2 305M -2 353M -2 252M -2 232M -2 199M -3 443M
othertotalStockholdersEquity 13 312M 13 041M 10 461M 13 647M 13 496M 13 311M 13 095M 14 651M 14 466M
totalStockholdersEquity 6 032M 6 778M 8 007M 10 360M 12 094M 12 866M 13 274M 17 254M 15 994M
totalEquity 6 071M 6 821M 8 047M 10 397M 12 129M 12 898M 13 303M 17 254M 15 994M
totalLiabilitiesAndStockholdersEquity 143 422M 141 937M 148 874M 134 711M 136 221M 135 367M 134 544M 138 805M 141 325M
minorityInterest 39M 43M 40M 37M 35M 32M 29M 33M 0
totalLiabilitiesAndTotalEquity 143 422M 141 937M 148 874M 134 711M 136 221M 135 367M 134 544M 138 805M 141 325M
totalInvestments 295M 299M 313M 306M 278M 295M 268M 269M 282M
totalDebt 71 079M 70 634M 74 001M 59 385M 60 746M 61 015M 62 093M 63 271M 69 606M
netDebt 63 822M 57 504M 55 934M 46 571M 47 459M 52 256M 55 382M 54 070M 57 774M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ABBV ABBV ABBV ABBV ABBV ABBV ABBV ABBV ABBV
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-07 2024-05-03 2024-02-20 2023-11-06 2023-08-07 2023-05-05 2023-02-17 2022-11-04
acceptedDate 2024-11-04 14:19:33 2024-08-07 15:00:51 2024-05-03 11:04:11 2024-02-20 12:45:17 2023-11-06 13:01:04 2023-08-07 13:10:46 2023-05-05 12:54:58 2023-02-17 12:54:29 2022-11-04 13:07:23
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1 564M 1 360M 1 359M 826M 1 781M 2 027M 241M 2 472M 3 952M
depreciationAndAmortization 2 079M 2 084M 2 074M 2 076M 2 235M 2 260M 2 127M 2 157M 2 205M
deferredIncomeTax -277M -16M -389M -1 391M -863M -368M -267M -516M -621M
stockBasedCompensation 181M 218M 348M 125M 130M 179M 313M 132M 126M
changeInWorkingCapital 750M -3 382M 247M 443M 2 643M 552M -825M 843M 1 338M
accountsReceivables 344M 178M -702M 339M 2M -80M -195M -416M 357M
inventory -64M -52M -75M 96M -55M -273M -185M -170M -17M
accountsPayables 267M -1 699M 362M 179M 2 554M 1 572M -465M 1 275M 778M
otherWorkingCapital 203M -1 809M 662M -171M 142M -667M 20M 154M 220M
otherNonCashItems 1 150M 7 966M 5 312M 2 674M 1 648M 1 669M 2 604M 2 340M 602M
netCashProvidedByOperatingActivities 5 447M 2 271M 4 040M 4 753M 7 574M 6 319M 4 193M 7 428M 7 602M
investmentsInPropertyPlantAndEquipment -249M -241M -193M -205M -219M -178M -175M -213M -177M
acquisitionsNet -8 294M -843M -9 199M -553M -157M -160M -353M -300M -100M
purchasesOfInvestments -24M -16M -6M -34M -8M -16M -19M -10M -17M
salesMaturitiesOfInvestments 507M 3M 6M 14M 5M 14M 22M 70M 1 410M
otherInvestingActivites -196M -848M -196M -22M 10M -1 000 000 26M 5M 170M
netCashUsedForInvestingActivites -8 256M -1 102M -9 588M -800M -369M -341M -499M -448M 1 286M
debtRepayment -403M -3 348M -14 764M -1 794M -2M -1 002M -1 351M -6 851M -2 701M
commonStockIssued 0 0 127M 31M 36M 48M 65M 0 0
commonStockRepurchased -17M -9M -1 324M -3M -4M -10M -1 955M -4M -4M
dividendsPaid -2 751M -2 750M -2 772M -2 626M -2 627M -2 625M -2 661M -2 506M -2 504M
otherFinancingActivites 99M 10M 24M -57M -64M -331M -290M -273M -309M
netCashUsedProvidedByFinancingActivities -3 072M -6 097M 10 819M -4 449M -2 661M -3 920M -6 192M -9 634M -5 518M
effectOfForexChangesOnCash 8M -9M -18M 23M -16M -10M 8M 23M -59M
netChangeInCash -5 873M -4 937M 5 253M -473M 4 528M 2 048M -2 490M -2 631M 3 311M
cashAtEndOfPeriod 7 257M 13 130M 18 067M 12 814M 13 287M 8 759M 6 711M 9 201M 11 832M
cashAtBeginningOfPeriod 13 130M 18 067M 12 814M 13 287M 8 759M 6 711M 9 201M 11 832M 8 521M
operatingCashFlow 5 447M 2 271M 4 040M 4 753M 7 574M 6 319M 4 193M 7 428M 7 602M
capitalExpenditure -249M -241M -193M -205M -219M -178M -175M -213M -177M
freeCashFlow 5 198M 2 030M 3 847M 4 548M 7 355M 6 141M 4 018M 7 215M 7 425M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-07-25 ET (fiscal 2024 q2)
2024 q1
2024-04-26 ET (fiscal 2024 q1)
2023 q4
2024-02-02 ET (fiscal 2023 q4)
2023 q3
2023-10-27 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-09 ET (fiscal 2022 q4)
2022 q3
2022-10-28 ET (fiscal 2022 q3)
2022 q2
2022-07-29 ET (fiscal 2022 q2)
2022 q1
2022-04-29 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 12:00 ET
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
2024-10-30 11:38 ET
AbbVie Reports Third-Quarter 2024 Financial Results
2024-10-29 12:00 ET
SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM
2024-10-28 12:00 ET
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
2024-10-24 15:30 ET
AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
2024-10-17 12:00 ET
U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
2024-10-16 12:00 ET
Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
2024-10-04 13:00 ET
Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
2024-10-02 12:00 ET
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
2024-10-01 12:00 ET
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
2024-09-27 16:13 ET
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
2024-09-26 12:00 ET
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
2024-09-25 11:00 ET
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
2024-09-24 12:00 ET
Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns
2024-09-20 11:32 ET
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
2024-09-11 12:30 ET
Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
2024-09-09 13:00 ET
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
2024-09-06 14:13 ET
AbbVie Declares Quarterly Dividend
2024-08-27 12:15 ET
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
2024-08-27 12:05 ET
SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
2024-08-19 18:05 ET
European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
2024-08-01 12:23 ET
AbbVie Completes Acquisition of Cerevel Therapeutics
2024-07-30 12:00 ET
Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day
2024-07-26 06:00 ET
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
2024-07-25 11:36 ET
AbbVie Reports Second-Quarter 2024 Financial Results
2024-07-12 12:30 ET
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
2024-07-10 12:00 ET
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
2024-07-02 12:00 ET
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
2024-07-01 12:00 ET
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
2024-06-28 06:00 ET
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
2024-06-27 13:26 ET
AbbVie Acquires Celsius Therapeutics
2024-06-27 12:30 ET
Introducing Allē Payment Plans, Powered by Cherry
2024-06-26 23:03 ET
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
2024-06-25 12:15 ET
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
2024-06-21 12:00 ET
AbbVie Declares Quarterly Dividend
2024-06-20 12:00 ET
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
2024-06-18 22:18 ET
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
2024-06-14 20:08 ET
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
2024-06-13 11:59 ET
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
2024-06-11 12:00 ET
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
2024-06-06 12:45 ET
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
2024-06-06 12:30 ET
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
2024-06-06 12:00 ET
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
2024-06-05 13:00 ET
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
2024-06-04 12:30 ET
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
2024-06-04 12:05 ET
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
2024-06-03 12:30 ET
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-31 06:00 ET
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
2024-05-28 12:00 ET
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
2024-05-23 20:05 ET
AbbVie Completes Acquisition of Landos Biopharma
2024-05-17 11:30 ET
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
2024-05-13 12:39 ET
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
2024-05-06 12:00 ET
AbbVie to Present at the Bank of America Securities Healthcare Conference
2024-04-26 11:35 ET
AbbVie Reports First-Quarter 2024 Financial Results
2024-04-25 12:00 ET
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
2024-04-23 12:00 ET
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
2024-04-18 12:31 ET
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
2024-04-12 11:30 ET
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
2024-04-09 12:00 ET
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
2024-04-04 12:00 ET
AbbVie to Host First-Quarter 2024 Earnings Conference Call
2024-04-03 12:30 ET
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
2024-03-25 16:40 ET
NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13
2024-03-25 15:00 ET
Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics
2024-03-25 12:31 ET
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
2024-03-25 12:30 ET
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
2024-03-22 19:02 ET
U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
2024-03-21 12:00 ET
ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024
2024-03-07 13:00 ET
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
2024-03-06 13:03 ET
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
2024-03-05 13:00 ET
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
2024-03-05 12:00 ET
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
2024-02-28 06:30 ET
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
2024-02-28 05:05 ET
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
2024-02-27 13:00 ET
AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-27 12:45 ET
U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
2024-02-22 13:05 ET
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
2024-02-21 13:00 ET
BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs
2024-02-20 14:00 ET
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
2024-02-19 13:30 ET
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
2024-02-15 17:03 ET
AbbVie Declares Quarterly Dividend
2024-02-06 17:00 ET
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases
2024-02-02 12:36 ET
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
2024-01-31 16:00 ET
Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-Expression
2024-01-25 08:00 ET
Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024
2024-01-23 13:00 ET
Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.
2024-01-09 07:00 ET
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union
2024-01-08 13:05 ET
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
2024-01-04 13:45 ET
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies
2024-01-04 13:00 ET
AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call
2024-01-02 13:00 ET
AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-09 17:00 ET
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
2023-12-06 21:30 ET
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
2023-12-05 13:45 ET
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
2023-11-29 13:45 ET
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
2023-11-27 12:00 ET
AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
2023-11-20 13:45 ET
Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever
2023-11-16 12:00 ET
Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
2023-11-08 13:45 ET
Natrelle® Unveils New "For Every BODY" Campaign
2023-11-01 12:45 ET
BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before
2023-10-27 11:38 ET
AbbVie Reports Third-Quarter 2023 Financial Results
2023-10-24 12:30 ET
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
2023-10-19 12:45 ET
Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project
2023-10-15 15:15 ET
AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
2023-10-12 09:25 ET
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
2023-10-11 12:30 ET
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
2023-10-10 12:45 ET
AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
2023-10-05 12:05 ET
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
2023-10-04 15:07 ET
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
2023-10-04 12:00 ET
AbbVie to Host Third-Quarter 2023 Earnings Conference Call
2023-10-03 11:00 ET
Allergan Aesthetics and Girls Inc. Partner to Speed the Entry of Young Women into Positions of Leadership in the STEM Field
2023-09-29 11:15 ET
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
2023-09-25 11:45 ET
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
2023-09-18 13:00 ET
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma Prominence
2023-09-13 15:00 ET
AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"
2023-09-12 12:30 ET
AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
2023-09-08 15:23 ET
AbbVie Declares Quarterly Dividend
2023-09-06 12:45 ET
Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs
2023-09-06 12:00 ET
AbbVie to Present at the Morgan Stanley Healthcare Conference
2023-08-30 13:00 ET
Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)
2023-08-28 12:45 ET
AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis
2023-08-17 06:00 ET
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
2023-08-01 12:45 ET
Allergan Aesthetics Announces First Ever JUVÉDERM® Day
2023-07-27 11:38 ET
AbbVie Reports Second-Quarter 2023 Financial Results
2023-07-26 13:00 ET
AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets
2023-07-26 12:05 ET
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
2023-07-24 12:05 ET
AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
2023-07-21 08:30 ET
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-06 12:00 ET
AbbVie to Host Second-Quarter 2023 Earnings Conference Call
2023-06-27 22:50 ET
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-26 12:00 ET
AbbVie Employees Volunteer During 8th Annual "Week of Possibilities" to Support Communities Globally
2023-06-23 12:04 ET
AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
2023-06-22 17:13 ET
AbbVie Declares Quarterly Dividend
2023-06-15 12:45 ET
Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
2023-06-13 12:45 ET
BOTOX® Cosmetic (onabotulinumtoxinA) Announces the Winners of the IFundWomen Grant Program
2023-06-09 07:00 ET
AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients
2023-06-06 12:00 ET
AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-31 06:30 ET
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
2023-05-25 12:45 ET
New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
2023-05-24 13:00 ET
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress
2023-05-19 16:34 ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2023-05-18 16:25 ET
U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
2023-05-15 12:45 ET
SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval
2023-05-06 11:30 ET
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
2023-05-02 12:00 ET
AbbVie to Present at the Bank of America Securities Healthcare Conference
2023-04-27 11:32 ET
AbbVie Reports First-Quarter 2023 Financial Results
2023-04-21 04:01 ET
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
2023-04-18 14:04 ET
Allergan Aesthetics Celebrates the Journeys of Women Surgeons with LIMITLESS
2023-04-17 23:41 ET
U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
2023-04-17 06:00 ET
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
2023-04-12 15:00 ET
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year
2023-04-04 12:00 ET
AbbVie to Host First-Quarter 2023 Earnings Conference Call
2023-04-03 12:00 ET
CoolSculpting® Elite Announces First Ever CoolMonth
2023-03-29 13:00 ET
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
2023-03-23 13:00 ET
AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
2023-03-23 12:30 ET
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
2023-03-22 12:45 ET
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
2023-03-18 14:03 ET
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
2023-03-15 12:03 ET
AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema
2023-03-13 12:03 ET
AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting
2023-03-08 13:45 ET
BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs
2023-03-08 13:00 ET
AbbVie to Present at the Barclays Global Healthcare Conference
2023-02-28 13:51 ET
AbbVie to Present at the Cowen 43rd Annual Health Care Conference
2023-02-27 11:00 ET
AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)
2023-02-27 07:00 ET
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
2023-02-23 09:59 ET
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
2023-02-16 17:41 ET
AbbVie Declares Quarterly Dividend
2023-02-09 12:44 ET
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
2023-01-25 16:42 ET
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
2023-01-18 13:00 ET
JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE
2023-01-17 13:00 ET
SkinMedica® Launches Even & Correct
2023-01-10 13:00 ET
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
2023-01-06 13:00 ET
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
2023-01-06 13:00 ET
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
2023-01-05 13:00 ET
AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call
2023-01-03 13:00 ET
AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-16 23:39 ET
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
2022-12-16 12:30 ET
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
2022-12-12 17:59 ET
AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year
2022-12-11 22:30 ET
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
2022-12-10 20:00 ET
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
2022-12-10 16:15 ET
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science
2022-12-06 13:00 ET
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
2022-12-06 07:00 ET
AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress
2022-11-23 13:00 ET
AbbVie to Present at the Evercore ISI HealthCONx Conference
2022-11-23 07:00 ET
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
2022-11-22 20:45 ET
AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting
2022-11-22 14:00 ET
AbbVie to Present at the Piper Sandler Healthcare Conference
2022-11-21 13:00 ET
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
2022-11-17 13:45 ET
Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet
2022-11-09 13:00 ET
AbbVie to Present at the Wolfe Research Healthcare Conference
2022-11-08 20:06 ET
AbbVie Presents Data from Extensive Portfolio at the American College of Rheumatology Convergence 2022
2022-11-07 17:31 ET
AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
2022-11-03 12:00 ET
Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness
2022-11-02 12:00 ET
Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
2022-10-28 12:45 ET
AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL)
2022-10-28 11:44 ET
AbbVie Reports Third-Quarter 2022 Financial Results
2022-10-24 11:00 ET
AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting
2022-10-21 20:42 ET
RINVOQ® (Upadacitinib) Receives Its Sixth U.S. FDA Approval
2022-10-20 13:00 ET
AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline
2022-10-17 13:00 ET
AbbVie Vice Chairman of External Affairs and Chief Legal Officer Laura J. Schumacher to Retire
2022-10-07 18:05 ET
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio at the 2022 American Society for Dermatologic Surgery Meeting
2022-10-04 12:00 ET
AbbVie to Host Third-Quarter 2022 Earnings Conference Call
2022-09-29 11:00 ET
AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022
2022-09-22 12:00 ET
The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery
2022-09-19 06:00 ET
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
2022-09-15 06:00 ET
AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress
2022-09-14 15:15 ET
AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards"
2022-09-13 12:45 ET
Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories
2022-09-10 07:20 ET
New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100
2022-09-09 14:26 ET
AbbVie Declares Quarterly Dividend
2022-09-08 08:30 ET
New MEASURE-AD Analyses Evaluate Clinical, Psychosocial and Economic Burdens in Atopic Dermatitis Patients
2022-09-08 08:00 ET
AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022
2022-09-07 12:45 ET
Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®
2022-09-07 12:00 ET
AbbVie to Present at the Morgan Stanley Healthcare Conference
2022-08-31 13:00 ET
SkinMedica® Launches Firm & Tone Lotion for Body
2022-08-30 12:00 ET
Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report
2022-08-29 12:00 ET
AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress
2022-08-24 23:21 ET
Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)
2022-08-17 12:45 ET
Experience the JUVÉDERM® Difference with Allergan Aesthetics
2022-08-03 12:45 ET
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
2022-07-29 11:41 ET
AbbVie Reports Second-Quarter 2022 Financial Results
2022-07-29 06:00 ET
RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis
2022-07-27 12:45 ET
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease
2022-07-26 06:00 ET
European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis
2022-07-25 12:00 ET
AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference
2022-07-20 11:00 ET
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
2022-07-18 06:00 ET
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
2022-07-08 12:00 ET
AbbVie to Host Second-Quarter 2022 Earnings Conference Call
2022-06-27 12:00 ET
Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities
2022-06-27 06:00 ET
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
2022-06-24 12:00 ET
New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer
2022-06-23 19:43 ET
AbbVie Declares Quarterly Dividend
2022-06-21 12:00 ET
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
2022-06-17 13:00 ET
Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry
2022-06-17 12:00 ET
SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
2022-06-11 12:45 ET
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
2022-06-10 07:15 ET
AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
2022-06-10 05:05 ET
New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment
2022-06-07 12:00 ET
AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting
2022-06-01 14:35 ET
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
2022-05-27 07:15 ET
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
2022-05-27 07:00 ET
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
2022-05-25 12:00 ET
AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference
2022-05-24 12:00 ET
AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
2022-05-23 12:00 ET
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
2022-05-23 06:00 ET
CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis
2022-05-20 12:15 ET
AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease
2022-05-16 12:00 ET
AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®
2022-05-16 11:30 ET
AbbVie and Cugene Announce Collaboration in Autoimmune Diseases
2022-05-12 15:39 ET
AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
2022-05-12 12:30 ET
AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education
2022-05-11 12:45 ET
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
2022-04-29 18:44 ET
RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
2022-04-29 11:43 ET
AbbVie Reports First-Quarter 2022 Financial Results
2022-04-28 12:30 ET
Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2022-04-28 12:00 ET
Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
2022-04-20 12:00 ET
Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
2022-04-19 12:30 ET
Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
2022-04-14 12:00 ET
AbbVie to Host First-Quarter 2022 Earnings Conference Call
2022-04-13 12:00 ET
BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
2022-04-12 12:00 ET
AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis
2022-04-05 12:30 ET
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Related Blurry Near Vision (Presbyopia)
2022-04-04 16:39 ET
Resorts World Las Vegas Secures First-of-its-Kind Agreement With Allergan Aesthetics
2022-03-29 12:00 ET
AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting
2022-03-21 12:30 ET
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting
2022-03-16 21:29 ET
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
2022-03-15 12:45 ET
Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours
2022-03-15 12:00 ET
AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
2022-03-11 07:00 ET
AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
2022-03-10 13:15 ET
AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
2022-03-08 22:06 ET
Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®
2022-03-08 21:32 ET
AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech
2022-03-01 13:30 ET
AbbVie to Present at the Cowen 42nd Annual Health Care Conference
2022-03-01 13:00 ET
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
2022-03-01 13:00 ET
Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie
2022-02-28 21:15 ET
AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S.
2022-02-28 13:00 ET
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
2022-02-24 16:22 ET
Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting
2022-02-24 13:00 ET
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
2022-02-22 13:15 ET
AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder
2022-02-17 16:33 ET
AbbVie Declares Quarterly Dividend
2022-02-10 14:00 ET
Healis Therapeutics acquires ownership of key botulinum toxin patent
2022-02-08 13:00 ET
FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows
2022-02-02 12:43 ET
AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
2022-02-01 13:45 ET
AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO)
2022-01-24 13:00 ET
Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)
2022-01-21 21:30 ET
U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
2022-01-14 18:10 ET
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
2022-01-11 13:45 ET
AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025
2022-01-07 14:00 ET
AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
2022-01-05 13:00 ET
AbbVie to Host Fourth-Quarter and Full-Year 2021 Earnings Conference Call
2022-01-04 13:15 ET
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
2022-01-04 13:00 ET
AbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-16 13:57 ET
Allergan Aesthetics Completes Acquisition of Soliton
2021-12-14 23:18 ET
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
2021-12-09 14:00 ET
VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available
2021-12-06 13:30 ET
Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
2021-12-03 21:15 ET
AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.
2021-11-30 13:05 ET
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
2021-11-23 13:15 ET
AbbVie to Present at the Evercore ISI Conference
2021-11-23 13:00 ET
AbbVie to Present at the Piper Sandler Healthcare Conference
2021-11-19 13:00 ET
Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting
2021-11-18 14:00 ET
New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission
2021-11-17 07:05 ET
AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
2021-11-15 13:30 ET
Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day
2021-11-10 13:30 ET
AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025
2021-11-10 13:00 ET
AbbVie to Present at the Wolfe Research Healthcare Conference
2021-11-09 13:45 ET
AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021
2021-11-09 13:31 ET
AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis
2021-11-08 13:30 ET
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting
2021-11-05 14:06 ET
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021
2021-11-04 13:05 ET
AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
2021-11-01 12:31 ET
AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021
2021-10-29 21:31 ET
U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
2021-10-29 11:50 ET
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
2021-10-29 11:40 ET
AbbVie Reports Third-Quarter 2021 Financial Results
2021-10-28 12:15 ET
AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease
2021-10-26 12:30 ET
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia
2021-10-15 12:35 ET
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU)
2021-10-11 12:42 ET
Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness
2021-10-07 12:16 ET
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
2021-10-07 12:15 ET
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
2021-10-05 12:00 ET
AbbVie to Host Third-Quarter 2021 Earnings Conference Call
2021-10-02 22:06 ET
AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021
2021-09-30 13:45 ET
AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress
2021-09-30 12:30 ET
AbbVie Presents New Analyses Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress
2021-09-28 22:42 ET
FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
2021-09-27 12:30 ET
Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals
2021-09-23 12:45 ET
AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress
2021-09-20 13:10 ET
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
2021-09-16 12:00 ET
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
2021-09-10 14:27 ET
AbbVie Declares Quarterly Dividend
2021-09-10 13:00 ET
AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021
2021-09-09 12:00 ET
AbbVie to Present at the Morgan Stanley Healthcare Conference
2021-09-08 13:10 ET
AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress
2021-08-24 12:00 ET
European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
2021-08-18 21:28 ET
New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine
2021-08-09 12:45 ET
SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
2021-08-04 16:01 ET
JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
2021-07-30 11:44 ET
AbbVie Reports Second-Quarter 2021 Financial Results
2021-07-29 12:30 ET
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
2021-07-27 12:30 ET
AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
2021-07-25 15:31 ET
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
2021-07-23 16:37 ET
DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients
2021-07-21 05:00 ET
Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)
2021-07-20 12:30 ET
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting
2021-07-16 12:30 ET
AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
2021-07-07 12:00 ET
AbbVie to Host Second-Quarter 2021 Earnings Conference Call
2021-06-29 12:00 ET
Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
2021-06-28 12:45 ET
AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO)
2021-06-25 12:30 ET
AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.
2021-06-25 06:30 ET
CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
2021-06-24 12:00 ET
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
2021-06-17 22:29 ET
AbbVie Declares Quarterly Dividend
2021-06-16 10:30 ET
Zhongchao Inc. Partners with a Subsidiary of AbbVie Inc. (NYSE: ABBV) for Medical Education Services
2021-06-12 11:02 ET
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study
2021-06-11 05:03 ET
New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment
2021-06-09 10:00 ET
Caraway Therapeutics Establishes Collaboration with AbbVie to Develop Novel Small Molecule Therapeutics for Parkinson’s Disease and Other Related Disorders
2021-06-08 12:45 ET
Allergan Aesthetics and BOTOX® Cosmetic (onabotulinumtoxinA) Put Real Stories at the Forefront in New Campaign
2021-06-07 15:30 ET
CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)
2021-06-04 13:00 ET
Results from IMBRUVICA® (ibrutinib) RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia (CLL)
2021-06-02 12:30 ET
AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-06-02 12:00 ET
Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year
2021-06-02 11:30 ET
AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
2021-06-02 11:00 ET
New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress
2021-05-26 12:15 ET
AbbVie to Present at Bernstein's 37th Annual Strategic Decisions Conference
2021-05-26 12:00 ET
AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting
2021-05-25 12:00 ET
AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
2021-05-25 12:00 ET
AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
2021-05-24 13:15 ET
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
2021-05-24 12:45 ET
The Lancet Publishes Results from Pivotal Global Phase 3 Program Evaluating RINVOQ® (upadacitinib) in Atopic Dermatitis
2021-05-20 12:00 ET
AbbVie to Present at the UBS Global Healthcare Virtual Conference
2021-05-19 12:00 ET
AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses
2021-05-12 12:00 ET
AbbVie to Present at the RBC Capital Markets Global Healthcare Conference
2021-05-10 12:30 ET
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
2021-04-30 11:42 ET
AbbVie Reports First-Quarter 2021 Financial Results
2021-04-27 12:30 ET
Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting
2021-04-23 12:00 ET
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
2021-04-07 13:01 ET
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
2021-04-07 12:00 ET
AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting
2021-04-02 21:18 ET
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
2021-04-01 12:45 ET
SkinMedica® Launches Neck Correct Cream for Neck and Décolleté
2021-04-01 12:31 ET
New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis
2021-03-31 12:00 ET
AbbVie to Host First-Quarter 2021 Earnings Conference Call
2021-03-30 12:00 ET
U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine
2021-03-17 12:45 ET
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis
2021-02-25 13:00 ET
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
2021-02-25 00:14 ET
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
2021-02-23 13:30 ET
New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use
2021-02-22 13:45 ET
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
2021-02-19 13:00 ET
AbbVie to Present at the Cowen 41st Annual Health Care Conference
2021-02-18 15:58 ET
AbbVie Declares Quarterly Dividend
2021-02-12 13:00 ET
AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2021-02-10 13:15 ET
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
2021-02-10 13:00 ET
BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
2021-02-03 12:38 ET
AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results
2021-01-26 13:45 ET
CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite
2021-01-25 16:30 ET
European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
2021-01-15 14:00 ET
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
2021-01-12 21:05 ET
Allergan Aesthetics Enters Into Option to Acquire Cypris Medical
2021-01-12 13:00 ET
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
2021-01-12 11:45 ET
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
2021-01-07 13:45 ET
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
2021-01-06 13:00 ET
AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-05 13:48 ET
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
2020-12-23 12:30 ET
IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM)
2020-12-11 12:32 ET
CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
2020-12-10 13:45 ET
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
2020-12-09 13:45 ET
Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis
2020-12-06 18:00 ET
Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients
2020-12-05 17:45 ET
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
2020-12-05 17:30 ET
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
2020-12-02 13:00 ET
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
2020-12-01 13:00 ET
AbbVie to Host Virtual Immunology Strategic Update
2020-11-24 13:00 ET
AbbVie to Present at the Evercore ISI Conference and Piper Sandler Healthcare Conference
2020-11-18 22:00 ET
AbbVie Announces Expiration and Final Results of Registered Exchange Offers
2020-11-16 13:00 ET
Allergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
2020-11-12 13:00 ET
AbbVie to Present at the Wolfe Research Healthcare Conference
2020-11-05 14:00 ET
AbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting
2020-10-30 11:47 ET
AbbVie Reports Third-Quarter 2020 Financial Results
2020-10-29 06:05 ET
AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis
2020-10-28 12:31 ET
AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020
2020-10-28 12:00 ET
Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia
2020-10-19 14:06 ET
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis
2020-10-19 12:56 ET
AbbVie Announces Commencement of Registered Exchange Offers
2020-10-16 23:34 ET
VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)
2020-10-09 13:00 ET
Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting
2020-10-07 12:00 ET
Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business
2020-10-06 12:00 ET
AbbVie to Host Third-Quarter 2020 Earnings Conference Call
2020-10-02 12:30 ET
AbbVie to Present New Data From 15 Abstracts at the 2020 Virtual Migraine Trust International Symposium
2020-09-28 12:00 ET
AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury
2020-09-16 12:00 ET
Malin Akerman Joins CoolSculpting® and CoolTone™ as U.S. Ambassador for the Allergan Aesthetics Body Contouring Portfolio
2020-09-14 12:00 ET
Allergan Aesthetics and Skinbetter Science Announce The DREAM Initiative™ To Advance Health Equity and Diversity in Aesthetics
2020-09-11 15:30 ET
AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®
2020-09-11 13:39 ET
AbbVie Declares Quarterly Dividend
2020-09-04 11:00 ET
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
2020-09-03 12:00 ET
AbbVie to Present at the Morgan Stanley Healthcare Conference
2020-08-25 12:45 ET
AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis
2020-08-25 12:00 ET
AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases
2020-08-25 10:30 ET
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
2020-08-12 21:45 ET
New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
2020-07-31 11:43 ET
AbbVie Reports Second-Quarter 2020 Financial Results
2020-07-29 12:45 ET
AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention
2020-07-28 12:45 ET
Third Pivotal Phase 3 Study Shows RINVOQ™ (upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients
2020-07-21 12:45 ET
RINVOQ™ (upadacitinib) Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis
2020-07-09 22:32 ET
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
2020-07-07 12:00 ET
AbbVie to Host Second-Quarter 2020 Earnings Conference Call
2020-01-13 13:00 ET
AbbVie to Host Fourth-Quarter and Full-Year 2019 Earnings Conference Call
2020-01-08 13:00 ET
AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition
2020-01-03 13:00 ET
AbbVie to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-09 13:00 ET
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
2019-12-07 14:00 ET
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
2019-12-07 12:30 ET
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
2019-11-21 13:30 ET
AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting
2019-11-21 09:00 ET
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
2019-11-20 13:00 ET
Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology
2019-11-18 13:00 ET
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes
2019-11-13 02:45 ET
AbbVie Prices $30 Billion of Senior Unsecured Notes
2019-11-12 16:15 ET
New Positive Data for RINVOQ(TM) (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting
2019-11-08 12:30 ET
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
2019-11-08 01:41 ET
AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes
2019-11-06 20:06 ET
AbbVie Announces Launch of Private Offering of Senior Unsecured Notes
2019-11-04 13:31 ET
AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting
2019-11-01 11:47 ET
AbbVie Reports Third-Quarter 2019 Financial Results
2019-10-29 13:03 ET
AbbVie Launches Let Me Be Clear to Empower People with Psoriasis to Speak Up and Seek Freedom from Their Disease
2019-10-25 12:11 ET
AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes
2019-10-24 12:30 ET
AbbVie to Present at the Wolfe Research Inaugural Healthcare Conference
2019-10-24 12:00 ET
AbbVie Announces Collaboration with Cystic Fibrosis Foundation
2019-10-18 11:30 ET
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
2019-04-17 15:00 ET
AbbVie Announces Call for Entries for the AbbVie CF Scholarship for the 2019-2020 Academic School Year
2019-04-01 20:30 ET
Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease
2019-03-26 05:00 ET
AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
2019-03-21 18:59 ET
AbbVie Donates $40 Million to Rebuild North Chicago Middle School
2019-03-07 13:46 ET
AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients
2019-03-01 13:00 ET
AbbVie to Present at the Barclays Global Healthcare Conference
2019-03-01 12:00 ET
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis

SEC forms

Show financial reports only

SEC form 10
2025-02-14 00:00 ET
AbbVie published news for 2024 q4
SEC form 8
2025-01-31 07:42 ET
AbbVie reported for 2024 q4
SEC form 8
2025-01-31 07:42 ET
AbbVie published news for 2024 q4
SEC form 8
2025-01-06 00:00 ET
AbbVie published news for 2024 q4
SEC form 8
2025-01-06 00:00 ET
AbbVie published news for 2024 q4
SEC form 10
2024-11-04 14:19 ET
AbbVie reported for 2024 q3
SEC form 8
2024-10-30 07:43 ET
AbbVie published news for 2024 q3
SEC form 8
2024-10-30 07:43 ET
AbbVie published news for 2024 q3
SEC form 8
2024-10-03 00:00 ET
AbbVie published news for 2024 q3
SEC form 8
2024-10-03 00:00 ET
AbbVie published news for 2024 q3
SEC form 10
2024-08-07 00:00 ET
AbbVie reported for 2024 q2
SEC form 8
2024-07-25 07:41 ET
AbbVie published news for 2024 q2
SEC form 8
2024-07-25 07:41 ET
AbbVie reported for 2024 q2
SEC form 8
2024-07-03 00:00 ET
AbbVie published news for 2024 q2
SEC form 8
2024-07-03 00:00 ET
AbbVie published news for 2024 q2
SEC form 10
2024-05-03 00:00 ET
AbbVie reported for 2024 q1
SEC form 8
2024-04-26 07:43 ET
AbbVie reported for 2024 q1
SEC form 8
2024-04-26 07:43 ET
AbbVie published news for 2024 q1
SEC form 8
2024-04-03 00:00 ET
AbbVie published news for 2024 q1
SEC form 8
2024-04-03 00:00 ET
AbbVie published news for 2024 q1
SEC form 10
2024-02-20 00:00 ET
AbbVie reported for 2023 q4
SEC form 8
2024-02-02 00:00 ET
AbbVie published news for 2023 q4
SEC form 8
2024-02-02 00:00 ET
AbbVie reported for 2023 q4
SEC form 8
2024-01-05 00:00 ET
AbbVie published news for 2023 q4
SEC form 8
2024-01-05 00:00 ET
AbbVie published news for 2023 q4
SEC form 10
2023-11-06 00:00 ET
AbbVie reported for 2023 q3
SEC form 8
2023-10-27 07:49 ET
AbbVie reported for 2023 q3
SEC form 8
2023-10-04 00:00 ET
AbbVie published news for 2023 q3
SEC form 10
2023-08-07 00:00 ET
AbbVie reported for 2023 q2
SEC form 6
2023-07-27 07:45 ET
AbbVie reported for 2023 q2
SEC form 8
2023-07-27 00:00 ET
AbbVie reported for 2023 q2
SEC form 6
2023-07-10 17:04 ET
AbbVie published news for 2023 q2
SEC form 6
2023-07-06 16:18 ET
AbbVie published news for 2023 q2
SEC form 8
2023-07-06 00:00 ET
AbbVie published news for 2023 q2
SEC form 6
2023-06-29 17:00 ET
AbbVie published news for 2023 q1
SEC form 6
2023-06-28 17:00 ET
AbbVie published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
AbbVie reported for 2023 q1
SEC form 8
2023-04-27 00:00 ET
AbbVie reported for 2023 q1
SEC form 8
2023-04-05 00:00 ET
AbbVie published news for 2023 q1
SEC form 10
2023-02-17 00:00 ET
AbbVie reported for 2022 q4
SEC form 8
2023-02-09 00:00 ET
AbbVie reported for 2022 q4
SEC form 8
2023-01-06 00:00 ET
AbbVie published news for 2022 q4
SEC form 10
2022-11-04 00:00 ET
AbbVie reported for 2022 q3
SEC form 8
2022-10-28 00:00 ET
AbbVie reported for 2022 q3
SEC form 8
2022-10-05 00:00 ET
AbbVie published news for 2022 q3
SEC form 10
2022-08-04 00:00 ET
AbbVie reported for 2022 q2
SEC form 8
2022-07-29 00:00 ET
AbbVie reported for 2022 q2
SEC form 8
2022-07-06 00:00 ET
AbbVie published news for 2022 q2
SEC form 10
2022-05-06 00:00 ET
AbbVie reported for 2022 q1
SEC form 8
2022-04-29 00:00 ET
AbbVie reported for 2022 q1
SEC form 8
2022-04-29 00:00 ET
AbbVie reported for 2022 q1
SEC form 8
2022-04-21 00:00 ET
AbbVie published news for 2022 q1
SEC form 10
2022-02-18 00:00 ET
AbbVie reported for 2021 q4
SEC form 8
2022-02-02 00:00 ET
AbbVie reported for 2021 q4
SEC form 10
2021-11-02 00:00 ET
AbbVie reported for 2021 q3
SEC form 8
2021-10-29 00:00 ET
AbbVie reported for 2021 q3
SEC form 10
2021-08-02 00:00 ET
AbbVie reported for 2021 q2
SEC form 8
2021-07-30 00:00 ET
AbbVie reported for 2021 q2
SEC form 10
2021-05-07 00:00 ET
AbbVie reported for 2021 q1
SEC form 8
2021-04-30 00:00 ET
AbbVie reported for 2021 q1